Instrument Inactif

Communiqués GT Biopharma Inc OTC Bulletin Board

Actions

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

21/05	Les plus fortes baisses de la mi-journée	MT
21/05	GT Biopharma fixe à 3,2 millions de dollars le prix de l'offre directe enregistrée d'actions et du placement privé simultané de bons de souscription d'actions	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	21/05	AQ
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update	15/05	AQ
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results	26/03	AQ
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split	01/02	AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS	07/12	AQ
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders	06/12	AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia	04/12	AQ
GT BIOPHARMA PRESENTED POSITIVE PRECLINICAL DATA FOR GTB-5550, A NOVEL TRIKE MOLECULE FOR TARGETED PROSTATE CANCER TREATMENT DURING THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING	07/11	AQ
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting	06/11	AQ
GT Biopharma Reports Third Quarter 2023 Financial Results	01/11	AQ
GT Biopharma : Failure to Satisfy Listing Rule - Form 8-K	23/08/23	PU
GT Biopharma Reports Second Quarter 2023 Financial Results	07/08/23	AQ
GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023	03/08/23	AQ
GT Biopharma : Submission of Matters to a Vote of Security Holders - Form 8-K	05/07/23	PU
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update	15/05/23	AQ
GT BIOPHARMA, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	04/05/23	AQ
GT Biopharma Names Charles J. Casamento to the Board of Directors	04/05/23	AQ
GT BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	30/03/23	AQ
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update	30/03/23	AQ
GT Biopharma : Failure to Satisfy Listing Rule - Form 8-K	01/03/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués GT Biopharma Inc OTC Bulletin Board

Actions

Communiqués

Filtres